Chapter 13. Development of Gene Therapy for Gaucher Disease
- Peter J. Quesenberry2,
- Gary S. Stein2,
- Bernard G. Forget3,
- Sherman M. Weissman3
Published Online: 13 MAY 2002
DOI: 10.1002/0471223956.ch13
Copyright © 1998 by Wiley-Liss, Inc.
Book Title

Stem Cell Biology and Gene Therapy
Additional Information
How to Cite
Barranger, J.A., Rice, E.O., Dunigan, J., Eljanne, M., Takiyama, N., Nimgaonkar, M., Mierski, J., Beeler, M., Kemp, A., Lancia, J., Lucot, S., Schierer-Fochler, S., Mannion-Henderson, J., Mohney, T., Swaney, W., Bahnson, A., Bansal, V. and Ball, E. (2002) Development of Gene Therapy for Gaucher Disease, in Stem Cell Biology and Gene Therapy (eds P. J. Quesenberry, G. S. Stein, B. G. Forget and S. M. Weissman), John Wiley & Sons, Inc., New York, USA. doi: 10.1002/0471223956.ch13
Editor Information
- 2
University of Massachusetts, Worcester, Massachusetts
- 3
Yale University School of Medicine, New Haven, Connecticut
Publication History
- Published Online: 13 MAY 2002
- Published Print: 27 AUG 1998
ISBN Information
Print ISBN: 9780471146568
Online ISBN: 9780471223955
- Summary
- Chapter
Keywords:
- Gaucher disease;
- gene transfer therapy;
- MFG-GC;
- CD34+ cells;
- transduction;
- preclinical studies;
- clinical trial;
- hematopoietic cells;
- prenatal gene therapy
Summary
The pathobiology of lysosomal storage disorders should dictate the target cell for gene transfer in the development of gene therapy. However, because the pathogenesis of these and most diseases is only partially defined, a variety of gene transfer approaches may need to be studied before a successful therapy is discovered (Table 1). Gaucher disease (GD) is the most common lysosomal storage disorder and is the focus of this chapter.
